
    
      Patients will be randomize to placebo or 15 mg pioglitazone for 12 months, and then be
      crossed over to the other arm. Patients will undergo MRI of the liver and kidney and
      MRspectroscopy of the lumbar spine (if they choose as this is ancillary study) three times
      during the study. Assessments will be every 3 months and include blood work, blood pressure,
      and body water assessments.
    
  